| Document |
Document Title |
|
WO/2019/117262A1 |
The present invention provides a composition for promoting cell adhesion containing a compound represented by general formula (I) or a salt thereof. {In the formula, each symbol is as defined in the description.}
|
|
WO/2019/117255A1 |
The present invention addresses the problem of providing an industrially preferable, economical, and environmentally friendly method for producing the 4,5-dihydroisoxazole represented by a formula (3). The present invention enables the c...
|
|
WO/2019/104888A1 |
Disclosed is an imine-type quaternary ammonium salt catalyst, wherein the catalyst has a general structure formula shown by formula I below; in the formula, R1 and R2, respectively, are independently selected from C1-C20 linear alkyl or ...
|
|
WO/2019/096209A1 |
Provided are a chiral 1,3-diarylimidazolium salt carbene precursor (S), a synthesis method therefor, a metal salt compound, and an application thereof. The chiral 1,3-diarylimidazolium salt carbene precursor catalyzes a reaction between ...
|
|
WO/2019/099371A1 |
Provided herein are compounds that are prodrugs for mesalazine. Generally, the compounds described herein correspond to a mesalazine molecule wherein the amino group is replaced by a novel protecting group. For example, in the compounds ...
|
|
WO/2019/087985A1 |
The purpose of the present invention is to obtain: a cured film that has high sensitivity, enables formation of a pattern of a low-tapered shape after development, is capable of suppressing a change in the dimensional width of pattern op...
|
|
WO/2019/084476A1 |
This disclosure relates to small molecule inhibitors of Fibroblast growth factor 23 (FGF-23) and related compositions and methods of treatment.
|
|
WO/2019/076926A1 |
The present invention relates to new classes of odorous oximes and their ketone intermediates (odorants) which are useful as fragrance or flavor materials in particular in providing cassis, catty, tropical, green, coniferous, thuya, flor...
|
|
WO/2019/071110A1 |
Glutamine antagonists and their use for treating oncological, immunological, and neurological diseases are disclosed. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder, ...
|
|
WO/2019/047846A1 |
Derivatives of hypocrellin with peri-position and 2-position simultaneously substituted by amino groups and a preparation method and application thereof are disclosed. The structural formula of the derivatives is as shown in the formulae...
|
|
WO/2019/040463A1 |
Provided are novel compounds of Formulas (I) and (II), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful as dual FKBP12/FKABP inhibitors. Also provided are pharmaceutical compositions co...
|
|
WO/2019/036349A1 |
This invention discloses the first example of palladium(ll)-catalyzed β-C(sp3)-H iodination or arylation of a wide range of ketones by using a commercially available aminooxyacetic acid auxiliary. This L, X-type directing group overcome...
|
|
WO/2019/022222A1 |
The present invention provides an additive composition for a culture medium, the composition containing a compound represented by formula (I) or a salt thereof. (In the formula, each symbol is as defined in the description.)
|
|
WO/2019/013112A1 |
An oxime ester compound represented by general formula (I). (In the formula, at least three moieties among R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 moieties are groups represented by general formula (II); and it is prefe...
|
|
WO/2018/235530A1 |
The present invention provides a metal alkoxide compound represented by general formula (1) (in the formula: R1 and R2 each independently denote an alkyl group having 1-4 carbon atoms; R3 denotes an alkyl group having 2 or 3 carbon atoms...
|
|
WO/2018/232298A1 |
The present invention provides a compound having the structure: and use of the compound for inhibiting the growth of or killing a fungus
|
|
WO/2018/228981A1 |
The invention relates to a process for the preparation of a compound represented by formula (I) wherein X is selected from the group consisting of -H, -halogen, linear or branched C1-C7 alkyl group, linear or branched C1-C5 alkoxy group,...
|
|
WO/2018/228857A1 |
The invention relates to novel laser markable compositions comprising developing agent precursors according to formula (I).
|
|
WO/2018/226374A1 |
Antidegradant compounds are disclosed, and methods of making them, that are represented by the formula (I), wherein each X is independently selected from the group consisting of ethyl, methyl, or hydrogen. Also disclosed are diimine inte...
|
|
WO/2018/199146A1 |
Provided is a novel method for producing amide compounds at high stereochemical selectivity. This method for producing amide compounds is provided with an amidation step for reacting an aminoester compound represented by general formula ...
|
|
WO/2018/196619A1 |
Disclosed are a fluorene oxime ester photoinitiator containing a polymerizable group, a preparation method and the use thereof, the fluorene oxime ester photoinitiator has the structure as shown in general formula (I), wherein R2 represe...
|
|
WO/2018/187479A1 |
A method of modulating ribonucleotide reductase activity in a neoplastic cell includes administering to the cell an amount of a triazole or an oxadiazole ribonucleotide reductase modulator (RRmod), the amount being effective to inhibit n...
|
|
WO/2018/184933A1 |
It is described an industrially viable and advantageous process for the preparation of racemic beta-aminosulfone (1), an useful intermediate for the preparation of N-(2-((1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)et
hyl)-2,3-dih...
|
|
WO/2018/166505A1 |
Disclosed are a compound represented by formula I or a pharmaceutically acceptable salt thereof, a preparation method therefor, and an application thereof in preventing or treating fatty liver or in preparing weight-reducing drugs.
|
|
WO/2018/157617A1 |
Disclosed is a process method for the synthesis of a ketoxime. The method comprises reacting a ketone and ammonia with hydrogen peroxide to obtain a ketoxime with a titanium silicon zeolite as a catalyst in an aqueous carbonate solution ...
|
|
WO/2018/159505A1 |
Provided are: a dissimilar-metal salt assembly which is a dendrimer capable of having a large number of, i.e., four or more types, particularly five or more types of dissimilar-metal salt compounds having dissimilar metals precisely inte...
|
|
WO/2018/154344A1 |
The compounds with the general formula (I) are disclosed where n1 is the number of carbon atoms connected to nitrogen atom by a double bond and can take on values between 25 and 41, and where n2 is the number of -CH2- groups and can take...
|
|
WO/2018/139485A1 |
The present invention addresses the problem of providing a dichloroglyoxime production method by which dichloroglyoxime, which can be used as an industrial anti-bacterial agent, a preservative, a slime control agent or the like, can be o...
|
|
WO/2018/140987A1 |
This patent mentioned the synthesis of new metal-organic framework based on hexameric titanium-oxo cluster. The novel material, termed MOF-902, was successfully synthesized and its crystal structure uncovered the 2-Dimensional (2D) layer...
|
|
WO/2018/134757A1 |
Oxo-nitrogenated iron complex having general formula (I): in which: R1 and R2, identical or different, represent a hydrogen atom; or they are selected from linear or branched, optionally halogenated C1 - C20, preferably C1-C15, alkyl gro...
|
|
WO/2018/135395A1 |
An electrolytic solution for non-aqueous secondary batteries, which comprises an electrolyte, an organic solvent and a metal complex represented by general formula (I); a non-aqueous secondary battery using the electrolytic solution for ...
|
|
WO/2018/134410A1 |
The present invention relates to the field of perfumery and flavor. More particularly, it concerns cleavable surfactants of formula (I) having a total hydrophilic-lipophilic balance (HLB) comprised between 3 and 18 and wherein A is a gro...
|
|
WO/2018/132766A1 |
The invention relates to methods, systems and kits for determining therapeutic effectiveness or toxicity of cancer-treating compounds that incorporate into or bind to DNA. In particular, the invention is directed to methods, systems and ...
|
|
WO/2018/128084A1 |
Provided is a polymerizable compound that has low-wavelength dispersion or reverse-wavelength dispersion, does not readily bubble when made into a coating material, has excellent substrate adhesion when made into a film-like polymer, and...
|
|
WO/2018/116158A1 |
The present invention relates to new compounds having hydroxyl, imino and carboxylic functionalities, processes for the production thereof and use thereof as antitumour agents for the treatment of solid tumours.
|
|
WO/2018/102427A1 |
Provided herein are methods of preparation of I by reacting i with acid where R1 and R2 are each independently a leaving group. Intermediates to make i are also claimed.
|
|
WO/2018/088436A1 |
Disclosed is an ammoximation catalyst useful in producing oximes from ketones with high yield and high selectivity by ammoximation reaction using hydrogen, oxygen and ammonia. The ammoximation catalyst contains (a) a titanosilicate and (...
|
|
WO/2018/085753A1 |
Provided herein are substituted hydrazone compounds useful as inhibitors of DEPTOR. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted hyd...
|
|
WO/2018/085737A1 |
Provided herein are compounds for use as photochromic molecular switches having very long thermal isomerization half-lives and switchable fluorescence properties both in solution and the solid state.
|
|
WO/2018/073828A1 |
Disclosed herein are compounds that are selective DNA primase and/or gyrase inhibitors. Further disclosed are pharmaceutical compositions comprising these compounds, and the uses of these compounds for treating disorders associated with ...
|
|
WO/2018/065997A1 |
An improved process for the production of concentrated aqueous solutions of hydrazine hydrate by ketazine method is described. In particular, it describes preparation of hydrazine hydrate by ketazine method using 50-70% hydrogen peroxide...
|
|
WO/2018/060959A1 |
The present disclosure relates to metformin glycinate and methods of using metformin glycinate for the treatment of diseases including diabetes mellitus, obesity, dyslipidemia, diseases associated with IL-10 up-regulation, and diseases o...
|
|
WO/2018/053587A1 |
The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.
|
|
WO/2018/054725A1 |
The present invention relates to a condensation reaction and/or addition reaction curable coating composition which contains (A) at least one polymer as the binder, (B) at least one crosslinking agent which can be reacted with component ...
|
|
WO/2018/044883A1 |
Disclosed are silane-functionalized amines useful as curing agents. Examples include the reaction product of: a) aspartate modified polyamine having at least two aspartate amine groups and at least one secondary non-aspartate amino group...
|
|
WO/2018/042871A1 |
A diazadienyl compound represented by general formula (I). In general formula (I), R1 represents a C1-6 linear or branched alkyl group, and M represents a nickel atom or manganese atom. In particular, a compound in which R1 in general fo...
|
|
WO/2018/033866A1 |
The present invention relates to a new chemical synthesis, intermediates and catalysts useful for the preparation of the neprilysin (NEP) inhibitor sacubitril, inter alia via nitro 5 compounds. It further relates to new intermediate comp...
|
|
WO/2018/021884A1 |
According to the present invention, a compound represented by chemical formula 1 is characterized by being coordinated with a metal ion, thereby enabling a bidirectional or multi-directional organometallic complex to be formed. Therefore...
|
|
WO/2018/021882A1 |
According to the present invention, a compound represented by chemical formula 1 is characterized by being coordinated with a metal ion, thereby enabling a bidirectional or multi-directional organometallic complex to be formed. Therefore...
|
|
WO/2017/067497A9 |
Disclosed are a monosubstituted or polysubstituted amphiphilic hypocrellin derivative, preparation method therefor, and uses thereof. In the present invention, the amphiphilic hypocrellin derivative having substituted functional groups s...
|
